Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NSABP-B-51||NSABP||A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1404||SWOG||A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0232||RTOG||A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0232||SWOG||Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant||Adult CIRB - Late Phase Emphasis||Completed|
|S9910||SWOG||Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|S1608||SWOG||Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1Y03||ECOG||Master Protocol for Pharmacogenetic and Genomic Studies.||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-50303||CALGB||Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-40||NSABP||A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1010||RTOG||A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|